SRAD vs. DOCS, YOU, WIX, SST, CNIC, NET, GVP, ARBB, SLP, and CYN
Should you be buying Stelrad Group stock or one of its competitors? The main competitors of Stelrad Group include Dr. Martens (DOCS), YouGov (YOU), Wickes Group (WIX), Scottish Oriental Smaller Cos (SST), CentralNic Group (CNIC), Netcall (NET), Gabelli Value Plus+ Trust (GVP), Arbuthnot Banking Group (ARBB), Sylvania Platinum (SLP), and CQS Natural Resources Growth and Income (CYN). These companies are all part of the "computer software" industry.
Stelrad Group vs.
Stelrad Group (LON:SRAD) and Dr. Martens (LON:DOCS) are both small-cap industrials companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.
Dr. Martens received 11 more outperform votes than Stelrad Group when rated by MarketBeat users.
Stelrad Group pays an annual dividend of GBX 8 per share and has a dividend yield of 5.6%. Dr. Martens pays an annual dividend of GBX 3 per share and has a dividend yield of 4.0%. Stelrad Group pays out 6,666.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Dr. Martens pays out 4,285.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Dr. Martens has higher revenue and earnings than Stelrad Group. Dr. Martens is trading at a lower price-to-earnings ratio than Stelrad Group, indicating that it is currently the more affordable of the two stocks.
Dr. Martens has a net margin of 7.89% compared to Stelrad Group's net margin of 5.25%. Stelrad Group's return on equity of 29.34% beat Dr. Martens' return on equity.
35.5% of Stelrad Group shares are held by institutional investors. Comparatively, 69.5% of Dr. Martens shares are held by institutional investors. 64.4% of Stelrad Group shares are held by company insiders. Comparatively, 4.4% of Dr. Martens shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Stelrad Group has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Dr. Martens has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500.
In the previous week, Stelrad Group and Stelrad Group both had 1 articles in the media. Stelrad Group's average media sentiment score of 1.27 beat Dr. Martens' score of 0.67 indicating that Stelrad Group is being referred to more favorably in the media.
Summary
Dr. Martens beats Stelrad Group on 8 of the 15 factors compared between the two stocks.
Get Stelrad Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRAD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Stelrad Group Competitors List
Related Companies and Tools
This page (LON:SRAD) was last updated on 2/6/2025 by MarketBeat.com Staff